Pfizer Completes Acquisition of Metsera for $7.0 Billion
ByAinvest
Thursday, Nov 13, 2025 11:28 am ET1min read
MTSR--
PFE--
Pfizer completes acquisition of Metsera, a clinical-stage biopharmaceutical company, for $7.0 billion. The acquisition adds a portfolio of promising therapeutic candidates to Pfizer's Internal Medicine pipeline. Pfizer will combine Metsera's innovative portfolio with its global development, manufacturing, and commercial infrastructure to advance candidate therapies for obesity and cardiometabolic diseases. The acquisition is expected to be dilutive through 2030, but will enable further investment in late-stage pipeline candidates.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet